NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced Wednesday that its independent directors approved an equity award to a new employee under the company’s 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The rule requires public disclosure of equity grants not made under a stockholder-approved plan.
The award, effective June 24, 2026, grants an option to purchase 10,000 shares of NeuroOne common stock at an exercise price of $3.27 per share, the closing price on the grant date. The option vests over four years, with 25% vesting on June 24, 2027, and the remainder in equal quarterly installments, contingent on continued employment. The ten-year term aligns with typical incentive stock option structures.
The recipient was not a previous employee or director of NeuroOne, underscoring the inducement nature of the grant. This approach is common for companies seeking to attract specialized talent, particularly in the competitive medical technology sector. NeuroOne, based in Eden Prairie, Minnesota, focuses on surgical solutions for neurological disorders, with FDA-cleared products including Evo Cortical Electrodes, Evo sEEG Electrodes, and the OneRF Ablation System for brain and trigeminal nerve procedures.
The inducement grant highlights NeuroOne’s strategy to bolster its workforce as it advances research and development in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. By offering equity as a recruitment tool, the company aims to secure expertise critical for innovation and market expansion. The disclosure also provides transparency to investors, as required by Nasdaq rules, ensuring they are aware of compensation practices that may dilute shares over time.
NeuroOne’s stock closed at $3.27 on June 24, the reference price for the grant. The company’s technology platform aims to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes. More information about NeuroOne is available at nmtc1.com.
